Skip to content
AnalystLens

Neurocrine Biosciences Quarterly Report for Q1 Ended Mar 31, 2025

Filing Date
Filed May 5, 2025
Period End
March 31, 2025
Security
NBIX
One revenue dollarkept$0.01
In the record · 2016–202610-K1210-Q338-K128

NBIX filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 128 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jan ’19Jan ’19
  2. Leadership change8-K · May ’22May ’22
  3. Leadership change8-K · Sep ’26Sep ’26

Summary

Summary of the 10-Q filed May 5, 2025. Cited figures are marked; the original filing is the authoritative source.

Neurocrine Biosciences, Inc. reported a sharp drop in first-quarter 2025 profitability despite growth in revenue.

Total revenues were $572.6 milliona versus $515.3 million a year earlier, driven by INGREZZA net product sales of $545.2 million (versus $506.0 million) and first CRENESSITY net product sales of $14.5 million following its December 2024 launch. However, operating income fell to $23.6 million from $99.3 million, as research and development expense rose to $263.2 million from $159.4 million, largely due to $37.5 million and $7.5 million milestone expenses payable to Takeda and Xenon, and selling, general and administrative expense rose to $276.5 million from $243.1 million. Net income declined to $7.9 million, or $0.08 per diluted share, from $43.4 million, or $0.42 per diluted share, with an unrealized loss of $30.6 million on equity investments also weighing on results.

The balance sheet shows total cash, cash equivalents and marketable securities of $1,758.8 millionb at March 31, 2025, down from $1,815.6 million at December 31, 2024. Operating cash flow was $64.8 million versus $130.3 million a year earlier, and the company repurchased $150.0 million of common stock during the quarter under its 2025 Repurchase Program, leaving $350.0 million available. Stockholders' equity declined to $2,535.7 million, and accumulated deficit moved to $(5.3) million from retained earnings of $29.2 million.

The filing also describes ongoing patent litigation: in April 2025 the company sued Zydus entities over a Paragraph IV ANDA filing for a generic INGREZZA SPRINKLE, and in January 2025 it sued Spruce Biosciences. Management stated it believes no pending claims are likely to have a material adverse effect individually or in the aggregate.

Key Highlights

  1. Total revenues rose to $572.6 million from $515.3 million, led by INGREZZA net product sales of $545.2 million versus $506.0 million.
  2. CRENESSITY, launched in December 2024, generated $14.5 million in net product sales in the first quarter of 2025.
  3. Operating income fell to $23.6 million from $99.3 million, as R&D expense increased to $263.2 million from $159.4 million.
  4. Net income was $7.9 million ($0.08 per diluted share) versus $43.4 million ($0.42 per diluted share) a year earlier, including a $30.6 million unrealized loss on equity investments.
  5. Operating cash flow was $64.8 million, down from $130.3 million, and total cash, equivalents and marketable securities were $1,758.8 million at March 31, 2025.
  6. The company repurchased $150.0 million of common stock in the quarter and had $350.0 million remaining under its $500.0 million 2025 Repurchase Program.
  7. The company filed suit against Zydus in April 2025 following a Paragraph IV ANDA filing for a generic INGREZZA SPRINKLE, and sued Spruce Biosciences in January 2025 seeking to invalidate a patent.

Follow one dollar

Of each $1.00 of revenue in Q1 FY2025, Neurocrine Biosciences kept $0.01.

  1. Revenue$572.6M100.0%
  2. Cost of revenue−$9.2M1.6%
  3. Gross profit$563.4M98.4%
  4. Operating costs−$539.8M94.3%
  5. Operating income$23.6M4.1%
  6. Interest, other & tax−$15.7M2.7%
  7. Net income$7.9M1.4%
Computed from 10-QQ1 FY2025filed May 5, 2025Computed from this filing’s revenue, gross profit, operating income and net income · right columngrey figure: share of revenue

Financial Statements

Q1 FY2025 against Q1 FY2024

Line itemQ1 FY2025Q1 FY2024Change
Revenue$572.60M$515.30M+11.1%
Cost of Revenue$9.20M$7.50M+22.7%
Gross Profit$563.40M$507.80M+10.9%
SG&A Expenses$276.50M$243.10M+13.7%
Operating Expenses$549.00M$416.00M+32.0%
Operating Income$23.60M$99.30M−76.2%
Net Income$7.90M$43.40M−81.8%
EPS (Basic)$0.08$0.43−81.4%
EPS (Diluted)$0.08$0.42−81.0%
Shares Outstanding (Basic)99.70M99.80M−0.1%
Shares Outstanding (Diluted)102.50M103.60M−1.1%

Frequently Asked Questions

  1. Why did net income decline so sharply despite higher revenue?

    Net income fell to $7.9 million from $43.4 million mainly because R&D expense rose to $263.2 million from $159.4 million, including $37.5 million and $7.5 million milestone expenses payable to Takeda and Xenon. SG&A also increased to $276.5 million from $243.1 million, reflecting commercial organization investment and CRENESSITY launch activities. A $30.6 million unrealized loss on equity investments further reduced results, though the prior year included $88.7 million in charges associated with convertible senior notes.

  2. How is INGREZZA performing, and what contributed to the growth?

    INGREZZA net product sales totaled $545.2 million in the first quarter of 2025, up from $506.0 million. The filing attributes the increase to underlying patient demand and improved gross-to-net dynamics. In April 2025, the company also expanded formulary access, which now covers two-thirds of TD and Huntington's disease Medicare beneficiaries.

  3. What is the status of the CRENESSITY launch?

    CRENESSITY, a first-in-class treatment for classic congenital adrenal hyperplasia, was launched in the U.S. in December 2024 and generated $14.5 million in net product sales in the first quarter of 2025. The filing notes that the successful launch depends on physician and patient adoption, and that the company has built a commercial team and hired a U.S. sales force for the product.

  4. How much cash does the company have, and how is it returning capital to shareholders?

    Total cash, cash equivalents and marketable securities were $1,758.8 million at March 31, 2025, compared with $1,815.6 million at December 31, 2024. During the first quarter, the company repurchased $150.0 million of common stock under its 2025 Repurchase Program, leaving $350.0 million available. Management states that existing capital resources, anticipated INGREZZA sales and investment income are expected to be sufficient for at least the next 12 months.

  5. What legal risks does the company face?

    The company is pursuing patent litigation against Zydus after receiving notice in March 2025 of an ANDA with a Paragraph IV certification for a generic INGREZZA SPRINKLE, and filed suits in the District of Delaware and the District of New Jersey in April 2025. It also filed suit against Spruce Biosciences in January 2025 to invalidate one of its patents. Management believes none of the pending claims is likely to have a material adverse effect individually or in the aggregate, but acknowledges litigation outcomes are unpredictable.